Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Flagged first, then by citations

Show all 218 references

2 of the 218 references couldn’t be matched to a known paper.

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 301–400 of 911

Evaluation and Treatment of Patients with Non–Small Cell Lung Cancer
Carr, L. L., Finigan, J. H., & Kern, J. A. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.08.001 · Cited by 30
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View
Edelman, M. J., Chevalier, T. L., & Soria, J. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182629e37 · Cited by 31
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
Ung, N., Putoczki, T. L., Stylli, S. S., Ng, I., Mariadason, J. M., Chan, T. A.-T., Zhu, H., & Luwor, R. B. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28179 · Cited by 30
Initial evaluation of the nonsmall cell lung cancer patient: diagnosis and staging
Almeida, F. A., Uzbeck, M. H., & Ost, D. E. (2010) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32833ab0b6 · Cited by 30
Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial–Mesenchymal Transition
Hsu, C.-Y., Lin, C., Jan, Y., Su, C., Yao, Y.-C., Cheng, H.-C., Hsu, T., Wang, P., Su, W., Yang, C., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2226oc · Cited by 30
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer
Spigel, D. R., Hainsworth, J. D., Shipley, D. L., Ervin, T. J., Kohler, P. C., Lubiner, E. T., Peyton, J. D., Waterhouse, D. M., Burris, H. A., & Greco, F. A. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307efe · Cited by 29
A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer
Ramnath, N., Daignault‐Newton, S., Dy, G. K., Muindi, J. R., Adjei, A. A., Elingrod, V. L., Kalemkerian, G. P., Cease, K. B., Stella, P. J., Brenner, D. E., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2109-x · Cited by 29
Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India
Veldore, V., Rao, R. M., Kakara, S., Pattanayak, S., Tejaswi, R., Sahoo, R., Venkataswamy, E., Prabhudesai, S., Krishnamoorthy, N., Tejaswini, B. N., et al. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117013 · Cited by 29
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial
Zwitter, M., Kovač, V., Rajer, M., Vrankar, M., & Smrdel, U. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833ab7a0 · Cited by 29
Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)
Rittmeyer, A., Горбунова, В. А., Vikström, A., Scherpereel, A., Kim, J.-H., Ahn, M., Chella, A., CHOUAID, C., Campbell, A., & Barlési, F. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a46bcf · Cited by 28
Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients
Vasile, E., Tibaldi, C., Leon, G. L., D’Incecco, A., & Giovannetti, E. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1880-3 · Cited by 28
What is the Best Strategy for Targeting EGF Receptors in Non-Small-Cell Lung Cancer?
Pirker, R. (2015) · Future Oncology · doi:10.2217/fon.14.178 · Cited by 28
Role of Genotyping in Non-Small Cell Lung Cancer Treatment
Bonanno, L., Favaretto, A. G., Rugge, M., Tarón, M., & Rosell, R. (2011) · Drugs · doi:10.2165/11597700-000000000-00000 · Cited by 29
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Pirker, R., & Filipits, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9612-6 · Cited by 28
SOX30 specially prevents Wnt-signaling to suppress metastasis and improve prognosis of lung adenocarcinoma patients
Han, F., Zhang, M., Liu, W., Sun, L., Hao, X., Li, Y., JIANG, X. H., Cao, J., & Liu, J.-Y. (2018) · Respiratory Research · doi:10.1186/s12931-018-0952-3 · Cited by 28
Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy
Cefalì, M., Epistolio, S., Ramelli, G., Mangan, D., Molinari, F., Martin, V., Freguia, S., Mazzucchelli, L., Froesch, P., Frattini, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061627 · Cited by 28
Nomogram Predicting Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Keam, B., Kim, D., Park, J. H., Lee, J., Kim, T. M., Lee, S., Chung, D. H., & Heo, D. S. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2013.120 · Cited by 28
A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy
Chen, Y.-M., Fan, W.-C., Tsai, C., Liu, S.-H., Shih, J.-F., Chou, T., Wu, C.-H., Chou, K., Lee, Y.-C., Perng, R.-P., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182121c09 · Cited by 28
The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and thep53status
Yusein-Myashkova, S., Stoykov, I., Gospodinov, A. G., Ugrinova, I., & Pasheva, E. A. (2016) · The Journal of Biochemistry · doi:10.1093/jb/mvw012 · Cited by 28
First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
Wang, S., Gao, A., Liu, J., & Sun, Y. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3516-1 · Cited by 28
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
Boni, C., Tiseo, M., Boni, L., Baldini, E., Recchia, F., Barone, C. A., Grossi, F., Germano, D., Matano, E., Marini, G., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.606 · Cited by 27
Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
Brodowicz, T., Ciuleanu, T., Crawford, J., Filipits, M., Fischer, J. R., Georgoulias, V., Gridelli, C., Hirsch, F. R., Jassem, J., Kosmidis, P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr381 · Cited by 27
A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
Elharrar, X., Barbolosi, D., Ciccolini, J., Meille, C., Faivre, C., Lacarelle, B., André, N., & Barlési, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2308-z · Cited by 27
Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis
Zeng, X., Li, J., Peng, L., Wang, Y., Tan, C., Chen, G., Wan, X., Lu, Q., & Yi, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088881 · Cited by 26
Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients
Paessens, B., von Schilling, C., Berger, K., Shlaen, M., Müller‐Thomas, C., Bernard, R., Peschel, C., & Ihbe‐Heffinger, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq759 · Cited by 27
Maintenance therapy in NSCLC: why? To whom? Which agent?
Novello, S., Milella, M., Tiseo, M., Banna, G. L., Cortinovis, D. L., Maïo, M. D., Garassino, M. C., Maione, P., Martelli, O., Vavalà, T., et al. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-50 · Cited by 28
Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2′-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles
Peng, L., Feng, L., Yuan, H., Benhabbour, S. R., & Mumper, R. J. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2014.03.016 · Cited by 27
PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells
de Souza, L. R., Muehlmann, L. A., do Santos, M. S. C., Ganassin, R., Simón‐Vázquez, R., Joanitti, G. A., Mosiniewicz-Szablewska, E., Suchocki, P., Morais, P. C., González‐Fernández, Á., et al. (2014) · Journal of Nanobiotechnology · doi:10.1186/preaccept-5192989891337222 · Cited by 27
Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer
Zietemann, V., & Duell, T. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.10.017 · Cited by 27
Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207
Tsukada, H., Yokoyama, A., Goto, K., Shinkai, T., Harada, M., Ando, M., Shibata, T., Ohe, Y., Tamura, T., & Saijo, N. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu176 · Cited by 27
Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy
Singh, N., Aggarwal, A. N., Kaur, J., & Behera, D. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000111 · Cited by 27
Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
Netterberg, I., Nielsen, E. I., Friberg, L. E., & Karlsson, M. O. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3366-x · Cited by 27
Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., de Marinis, F., Maïo, M. D., Ardizzoni, A., Belani, C. P., Cappuzzo, F., Ciardiello, F., Fidias, P. M., Paz-Ares, L. G., Perrone, F., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2011.12.011 · Cited by 26
Rationale and Design of MILES-3 and MILES-4 Studies: Two Randomized Phase 3 Trials Comparing Single-Agent Chemotherapy Versus Cisplatin-Based Doublets in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Gridelli, C., Rossi, A., Maïo, M. D., Leo, S., Filipazzi, V., Favaretto, A. G., Burgio, M. A., Cinieri, S., Bianco, R., Ciardiello, F., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.11.011 · Cited by 26
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Mubarak, N., Gaafar, R. M., Shehata, S., Hashem, T., Abigeres, D., Azim, H. A., El-Husseiny, G. A., Alhusaini, H., & Liu, Z. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-423 · Cited by 26
An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
Pujol, J.-L., Coffy, A., Camerini, A., Kotsakis, A. P., Mencoboni, M., Gusella, M., Pasini, F., Pezzuto, A., Banna, G. L., Bilir, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220988 · Cited by 26
Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer
Jiang, W., Cai, G., Hu, P. C., & Wang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.003 · Cited by 26
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
Yang, J. C., Srimuninnimit, V., Ahn, M., Lin, C., Kim, S., Tsai, C., Mok, T. S. K., Orlando, M., Puri, T., Wang, X., et al. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.008 · Cited by 28
Reproducibility of the EGFR immunohistochemistry scores for tumor samples from patients with advanced non-small cell lung cancer
Avilés‐Salas, A., Muñiz‐Hernández, S., Maldonado-Martínez, H. A., Chanona-Vilchis, J. G., Ramírez-Tirado, L.-A., Hernández‐Pedro, N., Dorantes-Heredia, R., Ruiz-Morales, J. M., Motola‐Kuba, D., & Arrieta, O. G. (2016) · Oncology Letters · doi:10.3892/ol.2016.5512 · Cited by 26
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Johnson, D. H., & Temin, S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.008524 · Cited by 26
Self-citation
The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease
Chen, Y. J., Chen, L. X., Han, M., Zhang, T. S., Zhou, Z. R., & Zhong, D. S. (2015) · Medicine · doi:10.1097/md.0000000000001451 · Cited by 25
Referral patterns in advanced non-small cell lung cancer: Impact on delivery of treatment and survival in a contemporary population based cohort
Noonan, K. L., Tong, K. M., Laskin, J. J., Melosky, B. L., Sun, S. B., Murray, N., & Ho, C. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.09.016 · Cited by 25
Self-citation
Simultaneous Multi-Antibody Staining in Non-Small Cell Lung Cancer Strengthens Diagnostic Accuracy Especially in Small Tissue Samples
Kayser, G., Csanádi, Á., Otto, C., Plönes, T., Bittermann, N., Rawluk, J. K., Passlick, B., & Werner, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056333 · Cited by 25
Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small
Smith, T. J., & Hillner, B. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1278 · Cited by 25
Self-citation
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
Koyama, N., Watanabe, Y., Iwai, Y., Kawamura, R., Miwa, C., Nagai, Y., Hagiwara, K., & Koyama, S. (2017) · Chemotherapy · doi:10.1159/000454944 · Cited by 25
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy
Weiss, J. M., Villaruz, L. C., Socinski, M. A., Ivanova, A., Grilley‐Olson, J. E., Dhruva, N., & Stinchcombe, T. E. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.011 · Cited by 24
Individualized therapy for patients with non-small cell lung cancer: Emerging trends and challenges
Langer, C. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.09.004 · Cited by 24
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing
Prabhash, K., Advani, S. H., Batra, U., Biswas, B., Chougule, A., Ghosh, M., Muddu, V. K., Sahoo, T. P., & Vaid, A. K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00903-y · Cited by 24
Pemetrexed With Platinum Combination as a Backbone for Targeted Therapy in Non–Small-Cell Lung Cancer
Stinchcombe, T. E., Borghaei, H., Barker, S. S., Treat, J., & Obasaju, C. K. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.07.002 · Cited by 25
Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
Lal, R., Hillerdal, G., Shah, R. N. H., Crosse, B., Thompson, J., Nicolson, M. C., Vikström, A., Potter, V. A., Visseren‐Grul, C., Lorenzo, M., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.003 · Cited by 24
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
Scagliotti, G. V., Gridelli, C., de Marinis, F., Thomas, M., Dediu, M., Pujol, J.-L., Manegold, C., Antonio, B. S., Peterson, P. M., John, W. J., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.005 · Cited by 24
The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care — an observational analysis on non-small-cell lung cancer patients
Ihbe‐Heffinger, A., Paessens, B., Berger, K., Shlaen, M., Bernard, R., von Schilling, C., & Peschel, C. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-012-1711-5 · Cited by 24
Data Set for Reporting of Lung Carcinomas: Recommendations From International Collaboration on Cancer Reporting
Jones, K. D., Churg, A., Henderson, D. W., Hwang, D. M., Wyatt, J. M., Nicholson, A. G., Rice, A. J., Washington, M. K., & Butnor, K. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0511-oa · Cited by 24
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
Park, S., Keam, B., Kim, S. H., Kim, K. H., Kim, Y. J., Kim, J.-S., Kim, T. M., Lee, S., Kim, D., Lee, J. S., et al. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.244 · Cited by 24
Management of Patients With Lung Cancer and Poor Performance Status
Gajra, A., Marr, A., & Ganti, A. K. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0098 · Cited by 24
Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience
Borghetti, P., Bonù, M. L., Roca, E., Pedretti, S., Salah, E., Baiguini, A., Greco, D., Triggiani, L., Maddalo, M., Giaj‐Levra, N., et al. (2018) · In Vivo · doi:10.21873/invivo.11219 · Cited by 24
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
Wakelee, H. A., & Gubens (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s6499 · Cited by 23
Double Burden of Malnutrition among Chinese Women of Reproductive Age and Their Social Determinants
Song, J., Zhang, J., Fawzi, W. W., & Huang, Y. (2020) · Nutrients · doi:10.3390/nu12103102 · Cited by 23
Squamous Cell Lung Cancer
Sabbula, B. R., & Anjum, F. (2021) · StatPearls · Cited by 23
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Reguart, N. (2010) · Cancer Management and Research · doi:10.2147/cmar.s5398 · Cited by 23
Chemotherapy in elderly patients with advanced non-small cell lung cancer
Quoix, É., Westeel, V., Zalcman, G., & Milleron, B. J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.006 · Cited by 23
Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer
Leung, L. K. S., Mok, T. S. K., & Loong, H. H.-F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012440015 · Cited by 23
Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel
Avelino, C. U. R., Cardoso, R. M., de Aguiar, S. S., & da Silva, M. J. S. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000004367 · Cited by 23
A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC
Pallis, A. G., Chandrinos, V., Pavlakou, G., Xenidis, N., Varthalitis, I. I., Vardakis, N., Vamvakas, L. N., Kontopodis, E., Rovithi, M. N., & Georgoulias, V. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1415-9 · Cited by 22
Early Response to Chemotherapy in Patients With Non–Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography
Novello, S., Vavalà, T., Levra, M. G., Solitro, F., Pelosi, E., Veltri, A., & Scagliotti, G. V. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.10.004 · Cited by 22
Maintenance Therapy in Advanced Non-small Cell Lung Cancer
Coate, L. E., & Shepherd, F. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d86e8b · Cited by 22
[Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome].
Shepherd, F. A., Douillard, J., & Blumenschein, G. R. (2013) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2013.04.09 · Cited by 22
Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines
Lee, C.-I., Liao, C., Chen, C.-S., Cheng, F., Chung, Y.-H., Wang, Y.-C., Ciou, S.-Y., Hsueh, W.-Y., Lo, T.-H., Huang, G.-R., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104715 · Cited by 22
Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
Huang, C., Ung, C. O. L., Wushouer, H., Bai, L., Li, X., Guan, X., & Shi, L. (2021) · International Journal of Health Policy and Management · doi:10.34172/ijhpm.2021.47 · Cited by 22
The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin
Li, P., Wang, K., Zhang, J., Zhao, L., Hong, L., Shao, C., & Sutherland, L. C. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.04.004 · Cited by 22
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials
Noonan, K. L., Ho, C., Laskin, J. J., & Murray, N. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000667 · Cited by 24
Self-citation
TMEM158andFBLP1as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells
Mohammed, A. E. S., Eguchi, H., Wada, S., Koyama, N., Shimizu, M., Otani, K., Ohtaki, M., Tanimoto, K., Hiyama, K., Gaber, M. S., et al. (2012) · Experimental Lung Research · doi:10.3109/01902148.2012.731625 · Cited by 22
A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells
Chen, C., Wu, M.-H., Chen, Y., Yen, T.-Y., Lin, Y., Chao, S.-H., Tala, S. D., Tsai, T., Su, T., & Lee, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.005 · Cited by 22
Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancer—a follow-up study
Ørum, M., Jensen, K., Gregersen, M., Meldgaard, P., & Damsgaard, E. M. S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.003 · Cited by 22
Adopting Integrated Care Pathways in Non–Small-Cell Lung Cancer: From Theory to Practice
Fasola, G., Rizzato, S., Merlo, V., Aita, M., Ceschia, T., Giacomuzzi, F., Lugatti, E., Meduri, S., Morelli, A., Rocco, M., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318257fbfe · Cited by 22
Vinorelbine for non-small cell lung cancer
Piccirillo, M. C., Daniele, G., Maïo, M. D., Bryce, J., Feo, G. D., Giudice, A. D., Perrone, F., & Morabito, A. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003774078 · Cited by 22
nab -paclitaxel for the management of patients with advanced non-small-cell lung cancer
Hirsh, V. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.881719 · Cited by 22
Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study
Su, S., Hu, Y., Ouyang, W., Lü, B., Ma, Z., Li, Q., Li, H., & Geng, Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-474 · Cited by 21
Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer
Plönes, T., Osei-Agyemang, T., Krohn, A., & Passlick, B. (2012) · Indian Journal of Surgery · doi:10.1007/s12262-012-0771-6 · Cited by 21
Target Therapy in Lung Cancer
Cafarotti, S., Lococo, F., Frösch, P., Zappa, F., & Dutly, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_6 · Cited by 21
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Polo, V., & Besse, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt529 · Cited by 21
Association Between CASP8 and CASP10 Polymorphisms and Toxicity Outcomes With Platinum-Based Chemotherapy in Chinese Patients With Non-Small Cell Lung Cancer
Qian, J., Qu, H., Yang, L., Yin, M., Wang, Q., Gu, S., Wu, Q., Zhao, X., Wu, W., Wu, J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0419 · Cited by 21
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes
Coate, L. E., & Shepherd, F. A. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011399306 · Cited by 22
Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial
Park, C., Oh, I., Kim, K. S., Choi, Y.-D., Jang, T. W., Kim, Y.-S., Lee, K.-H., Shin, K. C., Jung, C. Y., Yang, S. H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.002 · Cited by 21
Timeliness of Treatment Initiation and Associated Survival Following Diagnosis of Non–Small-Cell Lung Cancer in South Carolina
Bullard, J. T., Eberth, J. M., Arrington, A. K., Adams, S. A., Cheng, X., & Salloum, R. G. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000601 · Cited by 21
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer
Yi, L., Zhang, W. J., Zhang, H., Shen, J., Zou, J., Luo, P., & Zhang, J. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s169627 · Cited by 21
Development of a drug-eluting intraocular lens to deliver epidermal growth factor receptor inhibitor gefitinib for posterior capsule opacification prophylaxis
Kassumeh, S. A., Kueres, A., Hillenmayer, A., von Studnitz, A., Elhardt, C., Ohlmann, A., Priglinger, S. G., & Wertheimer, C. M. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119891042 · Cited by 21
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non–Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker
Ramlau, R., Thomas, M., Novello, S., Plummer, R., Reck, M., Kaneko, T., Lau, M. R., Margetts, J., Lunec, J., Nutt, J. E., et al. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.01.004 · Cited by 21
Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy
Ye, N., Bao, M., Xiaoxia, Y., Xie, D., & Jiang, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.06 · Cited by 20
Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)
Obasaju, C. K., Bowman, L., Wang, P., Shen, W., Winfree, K. B., Smyth, E. N., Boye, M. E., John, W. J., Brodowicz, T., & Belani, C. P. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt123 · Cited by 20
Phase II study of zoledronic acid combined with docetaxel for non‐small‐cell lung cancer: W est J apan O ncology G roup
Murakami, H., Yamanaka, T., Seto, T., Sugio, K., Okamoto, I., Sawa, T., Hirashima, T., Takeda, K., Atagi, S., Fukuoka, M., et al. (2014) · Cancer Science · doi:10.1111/cas.12448 · Cited by 20
Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials
Vale, C. L., Burdett, S., Fisher, D. J., Navani, N., Parmar, M., Copas, A. J., & Tierney, J. F. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.11.007 · Cited by 22
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment
Kim, H.-R., Lee, J. C., Kim, Y., Kim, K. S., Oh, I., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.008 · Cited by 21
Difference of Morphology and Immunophenotype between Central and Peripheral Squamous Cell Carcinomas of the Lung
Hayashi, T., Sano, H., Egashira, R., Tabata, K., Tanaka, T., Nakayama, T., Kashima, Y., Hori, T., Nunomura‐Nakamura, S., & Fukuoka, J. (2013) · BioMed Research International · doi:10.1155/2013/157838 · Cited by 20
Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges
Pallis, A. G., & Syrigos, K. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.006 · Cited by 20
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
Auliac, J. B., CHOUAID, C., Greiller, L., Monnet, I., Caer, H. L., Falchero, L., Corre, R., Descourt, R., Bota, S., Berard, H., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.006 · Cited by 20
Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
Nagji, A. S., Cho, S.-H., Liu, Y., Lee, J. K., & Jones, D. R. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0327 · Cited by 20
Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer
Li, W., Zhang, Z., Guo, L., Qiu, T., Ling, Y., Cao, J., Guo, H., Zhao, H., Li, L., & Ying, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6671 · Cited by 20
The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
Stinchcombe, T. E. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0394-4 · Cited by 20

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks